Skip to main content

Atopic Dermatitis Has Large Impact on Sexual Function Among Women

Medically reviewed by Carmen Pope, BPharm. Last updated on July 29, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, July 29, 2024 -- Most women with atopic dermatitis have impairment in sexual function, and about half consider that atopic dermatitis may influence their reproductive desire, according to a study published online June 11 in Acta Dermato-Venereologica.

Juan-Angel Rodriguez-Pozo, from the Virgen de las Nieves University Hospital in Granada, Spain, and colleagues examined the impact of atopic dermatitis on sexual function and reproductive wishes among women in a cross-sectional study conducted from February to March 2022. A total of 102 women with atopic dermatitis were recruited through online questionnaires.

The researchers found that 68.6 percent of the women noted impairment in sexual function, especially those with more severe disease and those with genital and gluteal involvement. About half (51 percent) of the women considered that atopic dermatitis may influence their gestational desire, especially those with gluteal involvement.

"Atopic dermatitis affects quality of life, sexuality, and gestational desire. Controllable factors such as the severity and extension of the symptoms enhance this impact. Despite all of this, patients scarcely consult on the issue with a dermatologist," the authors write. "Given this situation, an effort needs to be made by dermatologists to be concerned and to approach patients with atopic dermatitis in a more holistic way, emphasizing psychological and social aspects such as sexuality and reproductive desires."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted July 2024

Read this next

Cannabidiol Safe, May Lower Anxiety in Advanced Breast Cancer

FRIDAY, Dec. 20, 2024 -- For patients with advanced breast cancer and baseline clinical anxiety, cannabidiol (CBD) is safe and may reduce anxiety levels two to four hours after...

FDA Expands Approval of Vtama to Include Atopic Dermatitis

THURSDAY, Dec. 19, 2024 -- The U.S. Food and Drug Administration has approved Vtama (tapinarof) 1 percent cream for an additional indication -- the topical treatment of atopic...

FDA Approves Nemluvio for Moderate-to-Severe Atopic Dermatitis

WEDNESDAY, Dec. 18, 2024 -- The U.S. Food and Drug Administration has approved Nemluvio (nemolizumab) for the treatment of moderate-to-severe atopic dermatitis in patients...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.